Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New X-Ray tech aims to slash radiation for heart patients

NCT ID NCT06944509

Knowledge-focused Sponsor: Philips Clinical & Medical Affairs Global Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new X-ray system (Azurion R4.0) to an older version during heart procedures like angiography. The goal is to see if the new system lowers the radiation dose patients receive while still allowing doctors to work effectively. About 824 adults from several countries will take part, and the results will help improve safety in cardiac care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 824 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject will be undergoing a diagnostic angiography and/or coronary intervention /elective PCI. * Subject is able to give written informed consent. * Subject is 18 years of age or older, or of legal age to give informed consent per state or national law. Exclusion Criteria: * Subject with known contrast allergy that cannot be adequately premedicated. * Subject with previous contraindication for diagnostic angiography and/or diagnostic/elective PCI. * Subject participates in a potentially confounding drug or device study during the course of the study. * All vulnerable subjects such as pregnant or breast-feeding women, or any other subject who meets an exclusion criteria according to applicable national laws, if any. * Subject unwilling or unable to comply with the protocol and/or unable to understand verbal and/or written informed consent. * Expected use of non-standard contrast concentrations (e.g. dilution of contrast).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Aarhus university hospital

    Aarhus, Denmark

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Hospital Clinico San Carlos

    Madrid, Spain

  • NYP Columbia

    New York, New York, 80045, United States

  • University Hospital Královské Vinohrady

    Prague, Czechia

  • University of Colorado

    Denver, Colorado, 80204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.